Akums’ new medicine will be sold for sickle cell disease treatment. Credit: kikpokemon / Shutterstock.com.

Indian company Akums Drugs and Pharmaceuticals has introduced Hydroxyurea oral suspension, the country’s first room temperature-stable drug for treating sickle cell disease, according to a LinkedIn post.

The new formulation offers a cost-effective alternative to imported brands in the country.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Designed for ease of use across all age groups suffering from sickle cell disease, Hydroxyurea oral suspension will be offered as oral syringes to guarantee precise dosage, enhancing patient compliance and treatment efficacy.

The existing imported Hydroxyurea solution, which requires refrigeration between 2°C and 8°C, costs Rs77,000 ($928.9) in the Indian market.

Akums’ novel oral suspension drug will be available for Rs600, making it highly accessible to patients.

An inherited blood ailment, sickle cell disease changes the red blood cells into a sickle shape, which hampers their ability to transport oxygen across the body effectively.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Hydroxyurea aids red blood cells to maintain a rounder and larger shape, allowing for improved oxygen delivery throughout the body.

In a media statement posted on LinkedIn, Akums Drugs and Pharmaceuticals said: “In alignment with the objectives outlined in the national sickle cell anaemia mission, as announced by the Honourable Prime Minister Shri Narendra Modi Ji, Akums pledges to provide this medicine to the government at less than 1% of the cost of global brand imported in India, thus embodying the spirit of ‘Make in India’ and fostering widespread benefit to the masses.”